Bifeprunox in the Treatment of Schizophrenia

• Status: Completed
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Solvay Pharmaceuticals

Criteria

Inclusion Criteria:

• diagnosis of schizophrenia

• understand nature of study

• able to be managed in out-patient setting for long-term bifeprunox treatment

Exclusion Criteria:

• current primary diagnosis other than schizophrenia

• suicide risk

• diagnosis or history of substance abuse

• uncontrolled hypertension